Introduction
Acute promyelocytic leukemia (APL) is a distinct subset of acute myeloid leukemia clinically characterized at presentation by a severe coagulopathy. 1, 2 The advent of all-trans-retinoic acid (ATRA) and its inclusion in front-line treatment of APL has resulted in rapid amelioration of the bleeding tendency 3, 4 and considerable improvement of clinical outcome. However, some studies have suggested that ATRA-induced modifications in the balance between procoagulant and fibrinolytic properties of leukemic promyelocytes may favor the development of prothrombotic events. 5 In particular, cases of thromboembolic episodes have been reported in APL patients treated with ATRA. In these studies, it was suggested that rapid correction of the fibrinolysis syndrome mediated by ATRA may induce a state of hypercoaugulability which in turn may be exacerbated by the use of tranexamic acid leading to thrombotic events. [6] [7] [8] [9] [10] [11] [12] It is not known whether these events are associated with consistent biologic or clinical features such as leukemia cell phenotype and genotype, hyperleucocytosis or ATRA syndrome.
We describe here the characteristics of 11 APL patients who developed thrombotic complications during treatment with the all-trans retinoic acid and idarubicin (AIDA) protocol of the Italian Gruppo Italiano Malattie Ematologiche Ddell'Adulto (GIMEMA) group. 13 To better identify distinguishing features potentially associated with this complication, we compared the clinico-biological characteristics of these patients with those of a large control group receiving the same therapy and who did not develop thrombosis.
Patients and methods
During the period 1993-2001, 124 consecutive patients with newly diagnosed APL were observed and treated with the AIDA regimen at the Department of Cellular Biotechnology and Hematology of the University La Sapienza of Rome, Italy. APL was initially diagnosed according to French-American-British criteria and confirmed in all cases at the genetic level by reverse transcriptase-polymerase chain reaction identification of the promyelocytic leukemia/retinoic acid receptor (PML/RARa) hybrid as described previously.
14 Diagnostic studies included immunophenotypic characterization by flow-cytometry using a wide panel of monoclonal antibodies including CD13, CD33, HLA-DR, CD34, CD2, CD7, CD15, CD9, CD117, CD56, MPO. Following isolation of mononuclear cells from diagnostic bone marrow samples by centrifugation on a Ficoll-Hypaque density gradient, immunophenotypic studies were carried out by direct immunofluorescence. The percentage of positivity was determined by selecting blasts on the basis of light-scatter signals and comparing fluorescence intensity of each sample to that of isotype-matched controls. In particular, double staining with direct immunofluorescence was carried out to confirm CD2 and CD15 co-expression, each one used in combination with CD33. CD2 expression on leukemic cells was also established based on gating cells of large volume. Similarly, CD15 was detected on leukemic promyelocytes, on the basis of light scatter signal.
Total RNA was extracted from Ficoll-Hypaque-isolated leukemic blasts collected from bone marrow at diagnosis using the method of Chomczynsky and Sacchi. 15 RNA was reversetranscribed using random examers as primers and used for PML/ RARa amplification as described previously in the BIOMED-1 Concerted Action protocol. 16 The presence of FLT3 internal tandem duplication (ITD) was also investigated in all cases using the technique previously reported elsewhere. 17 Data concerning coagulation parameters at diagnosis and at the onset of thrombotic events (prothrombin time, partial thromboplastin time (PTT), fibrinogen, fibrinogen/fibrin degradation products) were recorded and defined normal or abnormal according to criteria described previously. 18 The AIDA protocol consisted of ATRA (45 mg/m 2 until hematologic complete remission) and idarubicin (12 mg/mq on day 2, 4, 6, 8), followed by three polychemotherapy consolidation cycles as reported previously. 13 The diagnosis of venous thrombosis of extremities was established only if confirmed by compression ultrasonography or color Doppler ultrasonography. The diagnosis of cardiac ischemic condition was based on electrocardiographic and cardiac enzymatic modifications and the diagnosis of intraventricular thrombosis was established by computed tomography (CT scan) and eco color Doppler cardiac imaging. Statistical analysis was performed using SPSS version 6.0 software; Wilcoxon-Mann-Whitney test was performed for comparison of non-parametric series and Fisher's exact test was used to compare categories. Values of Po0.05 were considered of statistical significance.
Results
The main clinical and biological characteristics at presentation of the 11 patients who developed thrombosis are shown in Table 1 . According to the relapse-risk score established by Sanz et al., 19 six patients were classified as high risk, three patients as intermediate risk and two patients as low risk. Three patients were morphologically categorized as having the microgranular variant M3v type. As to PML/RARa transcript type, eight patients had the short (bcr3) and three patients the long (bcr1) gene fusion isoform. With respect to immunophenotype, in addition to the typical MPO þ ve, CD33 þ ve, CD9 þ and HLA-DR Àve profile, all 11 patients disclosed some aberrant immunophenotypic features including expression of CD2 (six cases), CD15 (four cases) or both CD2 and CD15 (one case). FLT3-ITD was documented in seven cases, concomitantly with the expression of CD2 in five patients, with CD15 in one patient, and with either antigens in one patient.
The site of thrombosis and the analysis of potential predisposing factors in the 11 patients are described in Table 2 . Seven patients had the thrombotic event during induction chemotherapy, whereas four patients developed thrombosis after completing induction, before starting consolidation therapy. Only 3/11 patients had coagulation impairment at the time of diagnosis (prolongation of PTT and increased crosslinked fibrin degradation product). Two patients experienced ATRA syndrome during induction. ATRA syndrome-related symptoms occurred in these two patients at day þ 3 and þ 4 from the start of therapy and in Occurrence of thrombotic events in APL M Breccia et al both cases the syndrome manifested several days before the onset of thromboses that occurred at day þ 20 and þ 32 in these two cases. Only one patient had a remote anamnesis of thromboses with a sudden stroke occurring 10 years before the onset of APL.
As concerns the site of thrombosis, two patients experienced intraventricular localization in the absence of cardiac arrhythmia and four patients developed sub-endocardic ischemia owing to a coronary occlusion with cardiac enzymatic modifications during induction therapy. In all these patients, ATRA therapy was temporarily discontinued and cardiac parameters were monitored until the resolution of signs and symptoms. In five additional cases the diagnosis was of deep venous thrombosis of the leg occurring in one patient during induction and in four patients immediately after the discontinuation of ATRA therapy. Only one patient out of five investigated was found to be carrier of a thrombophilic state consisting of heterozygosity for prothrombin gene mutation.
The comparison of the main presenting features of patients with and without thrombosis in the whole series of patients is shown in Table 3 . Significant differences between the two groups were found in white blood cell (WBC) number (P ¼ 0.002), type of PML/RARa transcript (with prevalence of bcr3 in patients with thrombotic events, P ¼ 0.01), higher incidence of FLT3-ITD (P ¼ 0.02), CD2 positivity (P ¼ 0.0001) and CD15 positivity (P ¼ 0.01).
Finally, we analyzed retrospectively the incidence of thrombotic events in 80 APL patients treated at our institution with chemotherapy alone in the pre-ATRA era. None of these patients developed thrombotic conditions, whereas three events occurred at the time of relapse in patients who were re-induced with ATRA (one patient had ischemic heart disease, one patient fatal thromboembolism and one patient deep venous thrombosis of the leg). No information on immunophenotype or molecular characterization at relapse was available in these cases.
Discussion
In this report, we found a close relationship between some biological features of leukemic cells and development of thrombotic events in patients with APL treated with ATRA and chemotherapy. These characteristics included CD2 and/or CD15 expression, bcr3 PML/RARa transcript type, FLT3-ITD and elevated WBC.
The biological and clinical consequences of CD2 expression on leukemic promyelocytes are uncertain. CD2, an antigen normally expressed on the surface of T cells, can mediate the adhesion to several molecules, such as the ubiquitously expressed CD58 or CD59 expressed on platelets and erythrocytes. 20, 21 As suggested by Claxton et al., 21 CD2 overexpression in APL may play a role in leucoagglutination, contributing to tissue damage by microvascular occlusion. Biondi et al. 22 and Guglielmi et al. 23 found a significant association between CD2 expression and the microgranular M3v subtype. More recently, Albano et al. 24 reported an increased incidence of M3v, bcr3, leucocytosis, low platelet count and higher percentage of peripheral blast in patients CD2 þ . In our series, CD2 was associated with leucocytosis, which may represent a further triggering event for thrombosis. However, we note that 5/11 patients in our series had no hyperleucocytosis at presentation and, in four of these five, blast cells were also negative for CD2 expression, but positive for CD15 at diagnosis, suggesting that other unknown mechanisms not involving CD2 and leucocytosis are involved in the pathogenesis of thrombosis in this clinical context. As to CD15, this antigen mediates the adhesion to activated endothelial cells through selectins ligand, and favors the first rolling event (E-selectins dependent). 25 Although it has been reported that both CD2 and CD15 expression are modulated by ATRA, [26] [27] [28] we did not evaluate in the present study the in vivo induction of CD2 and CD15 levels during treatment, therefore a role for these antigens in thrombotic events cannot be definitely established. In this respect, it would be interesting to evaluate other molecules involved in leukocyte activation which may be detected at baseline or induced following ATRA treatment in this patients.
We and others described the frequent association of the FLT-ITD mutation in patients with APL and reported its correlation at diagnosis with elevated WBC count and the PML/RARa bcr3 isoform. 29, 30 FLT-ITD is recognized as an adverse factor for response to therapy and outcome in AML, 31, 32 although its prognostic significance in APL is less clear. As to the biological role of this genetic alteration, it is known that FLT-ITD leads to constitutive activation of the receptor resulting in increased proliferation of leukemic cells. Significantly, five of six patients defined as high risk based on WBC count had FLT-ITD in our series. In agreement with these clinical findings, Gale et al. 30 reported in FLT3-ITD þ APL patients increased expression of genes with functions either known or postulated to be associated with cell growth and cell cycle control. Recently, Marasca et al. 32 reported gene expression profiling and FLT3 mutational status in a series of APL patients, and found that patients ITD þ had increased expression in their blasts of genes regulating blood coagulation (CD97, PTX3, H963) and cell adhesion (AMIGO2, LGALS 1-2).
Previous studies reported a variable prevalence of thrombosis in APL ranging from 2 to 10-15%. 10, 12, [33] [34] [35] [36] A number of factors may account for this variability including treatment with or without ATRA, concomitant use of chemotherapy, different disease characteristics in the analyzed series and, finally, heterogeneity in supportive care particularly as concerning the prophylactic use of tranexamic acid. The concomitance of ATRA therapy and tranexamic acid was described as a possible triggering mechanism favoring the occurrence of thrombosis in some case reports; 37, 38 patients who developed thrombosis were not given concomitant chemotherapy for induction in these studies. We note that in our series all patients received tranexamic acid for prophylaxis and a simultaneous ATRA plus chemotherapy induction therapy.
We also analyzed retrospectively our series of APL patients receiving chemotherapy alone in the pre-ATRA era. No cases of thromboses were recorded in this series, whereas three patients relapsing after chemotherapy developed thrombosis during Occurrence of thrombotic events in APL M Breccia et al salvage with ATRA. Although the role of tranexamic acid in the pathogenesis of thrombosis remains unclear, its benefit in the prevention of hemorrhage has been recently questioned by the Spanish PETHEMA group who observed a similar incidence and severity of hemorrhagic events in patients receiving or not tranexamic acid during the induction treatment with the AIDA protocol. 19 In summary, our study suggests that the risk of developing thrombotic events in APL patients treated with ATRA and chemotherapy is associated with consistent phenotypic and genotypic features of leukemia cells. Therefore, detection of these characteristics in association to leucocytosis should alert clinicians on increased thrombotic risk and may induce supportive treatment modifications in these patients, such as avoiding or withdrawal of tranexamic acid. Further studies are warranted to investigate the mechanistic link between these features and the pathogenesis of thrombosis in these patients.
